167 related articles for article (PubMed ID: 23899839)
1. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification.
Noro R; Honda K; Tsuta K; Ishii G; Maeshima AM; Miura N; Furuta K; Shibata T; Tsuda H; Ochiai A; Sakuma T; Nishijima N; Gemma A; Asamura H; Nagai K; Yamada T
Ann Oncol; 2013 Oct; 24(10):2594-2600. PubMed ID: 23899839
[TBL] [Abstract][Full Text] [Related]
2. Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas.
Noro R; Honda K; Nagashima K; Motoi N; Kunugi S; Matsubayashi J; Takeuchi S; Shiraishi H; Okano T; Kashiro A; Meng X; Yoshida Y; Watanabe S; Usuda J; Inoue T; Wilber H; Ikeda N; Seike M; Gemma A; Kubota K
Cancer Sci; 2022 Mar; 113(3):1002-1009. PubMed ID: 34845792
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.
Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH
Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777
[TBL] [Abstract][Full Text] [Related]
4. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
5. MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas.
Jin Y; Sun PL; Kim H; Seo AN; Jheon S; Lee CT; Chung JH
Ann Surg Oncol; 2014 Feb; 21(2):621-8. PubMed ID: 24212721
[TBL] [Abstract][Full Text] [Related]
6. Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance.
Yamamoto S; Tsuda H; Honda K; Onozato K; Takano M; Tamai S; Imoto I; Inazawa J; Yamada T; Matsubara O
Mod Pathol; 2009 Apr; 22(4):499-507. PubMed ID: 19151661
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.
Miura N; Kamita M; Kakuya T; Fujiwara Y; Tsuta K; Shiraishi H; Takeshita F; Ochiya T; Shoji H; Huang W; Ohe Y; Yamada T; Honda K
Oncotarget; 2016 May; 7(22):33165-78. PubMed ID: 27121206
[TBL] [Abstract][Full Text] [Related]
8. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients.
Tanaka A; Sueoka-Aragane N; Nakamura T; Takeda Y; Mitsuoka M; Yamasaki F; Hayashi S; Sueoka E; Kimura S
Lung Cancer; 2012 Jan; 75(1):89-94. PubMed ID: 21733594
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of gene amplification of ACTN4 in stage I and II oral tongue cancer.
Kakuya T; Mori T; Yoshimoto S; Watabe Y; Miura N; Shoji H; Onidani K; Shibahara T; Honda K
Int J Oral Maxillofac Surg; 2017 Aug; 46(8):968-976. PubMed ID: 28385383
[TBL] [Abstract][Full Text] [Related]
10. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.
Cappuzzo F; Marchetti A; Skokan M; Rossi E; Gajapathy S; Felicioni L; Del Grammastro M; Sciarrotta MG; Buttitta F; Incarbone M; Toschi L; Finocchiaro G; Destro A; Terracciano L; Roncalli M; Alloisio M; Santoro A; Varella-Garcia M
J Clin Oncol; 2009 Apr; 27(10):1667-74. PubMed ID: 19255323
[TBL] [Abstract][Full Text] [Related]
11. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
Sholl LM; Yeap BY; Iafrate AJ; Holmes-Tisch AJ; Chou YP; Wu MT; Goan YG; Su L; Benedettini E; Yu J; Loda M; Jänne PA; Christiani DC; Chirieac LR
Cancer Res; 2009 Nov; 69(21):8341-8. PubMed ID: 19826035
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
[TBL] [Abstract][Full Text] [Related]
13. Copy number gain of ACTN4 is associated with poor prognosis in patients with upper urinary tract urothelial carcinoma.
Kawamura K; Miyai K; Sato K; Matsukuma S; Honda K; Ito K; Tsuda H
Cancer Sci; 2023 Aug; 114(8):3411-3422. PubMed ID: 37226638
[TBL] [Abstract][Full Text] [Related]
14. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.
Tang X; Kadara H; Behrens C; Liu DD; Xiao Y; Rice D; Gazdar AF; Fujimoto J; Moran C; Varella-Garcia M; Lee JJ; Hong WK; Wistuba II
Clin Cancer Res; 2011 Apr; 17(8):2434-43. PubMed ID: 21257719
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutant allele-specific imbalance in lung adenocarcinoma.
Chiosea SI; Sherer CK; Jelic T; Dacic S
Mod Pathol; 2011 Dec; 24(12):1571-7. PubMed ID: 21743433
[TBL] [Abstract][Full Text] [Related]
18. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
19. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
20. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
